LoadingLoadingLoadingNet selling: insiders sold $330.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Millennium
$130.7M
added
Qube Research
$53.4M
added
Sells/Trims (1)
D.E. Shaw
$58.8M
sold
No tracked top-trader positions in UTHR as of Oct 21, 18:27 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 5, 2026
Financial period
Q2 2026
Earnings per share
$7.03 expected
Revenue
$804.6M expected
Estimates as of Oct 21, 2026
EPS expected
$4.40 to $7.26
Revenue expected
12 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $7.27 / $7.03Yahoo Finance | +3.47% beat | $783.3M $804.6M expected | -2.65% miss |
| Mar 31, 2026 | May 6, 2026 | $5.82 / $7.04Yahoo Finance | -17.38% miss | $781.5M No estimate | Unavailable |
| Dec 31, 2025 | Feb 25, 2026 | $7.70 / $7.24Yahoo Finance | +6.35% beat | $790.2M No estimate | Unavailable |
| Sep 30, 2025 | Oct 29, 2025 | $7.16 / $7.31Yahoo Finance | -2.03% miss | $799.5M No estimate | Unavailable |
| Jun 30, 2025 | Jul 30, 2025 | Unavailable | - | $798.6M No estimate | Unavailable |
| Mar 31, 2025 | Apr 30, 2025 | $6.63 / $6.54Alpha Vantage | +1.38% beat | $794.4M No estimate | Unavailable |
| Dec 31, 2024 | Feb 26, 2025 | $6.19 / $6.27Alpha Vantage | -1.23% miss | $735.9M No estimate | Unavailable |
| Sep 30, 2024 | Oct 30, 2024 | $7.07 / $7.12Alpha Vantage | -0.70% in line | $748.9M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $799.5M | $790.2M | $781.5M | $783.3M |
| Cost of what it sold | $100.9M | $103.4M | $133.4M | $99.5M |
| Gross profit | $698.6M | $686.8M | $648.1M | $683.8M |
| What it spent | ||||
| Research and development | $127.5M | $139.5M | $138.2M | $146.3M |
| Sales and admin | $153.5M | $157.1M | $155.4M | $137.9M |
| Other operating costs | $28.3M | $32.7M | $28.7M | $68.8M |
| Total operating expenses | $309.3M | $329.3M | $322.3M | $353.0M |
| What was left | ||||
| Operating profit | $389.3M | $357.5M | $325.8M | $330.8M |
| Interest on debt | $3.0M | $3.1M | $3.0M | $2.9M |
| Profit before tax | $438.0M | $444.0M | $318.3M | $372.7M |
| Tax | $99.3M | $79.7M | $43.4M | $39.7M |
| Net profit | $338.7M | $364.3M | $274.9M | $333.0M |
| EBITDA | $462.9M | $469.9M | $343.9M | $399.8M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is mixed
Form 4 United Therapeutics Corporation: Martine A. Rothblatt (Director, Chairperson & CEO) For: 16 October
NeutralOct 19United Therapeutics chairperson & CEO sells $5.08m in shares
Leans bearishOct 19After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares.
NeutralOct 19Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years
BullishOct 19Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed.
BullishOct 19United Therapeutics chairperson & CEO sells $5.19m in stock By Investing.com
NeutralOct 17United Therapeutics chairperson & CEO sells $5.19m in stock
NeutralOct 17Form 4 UNITED THERAPEUTICS Corp For: Oct 15 Filed by: MAHON PAUL A
Leans bearishOct 16
